UNOS awarded contracts to redesign ASTS Web site, collect data for NIH heart device registry.
UNOS also announced that it has been selected as a subcontractor in the establishment of a national registry of patients receiving mechanical circulatory support as either a bridge to transplant or as destination therapy for heart failure.
ASTS Web site
The ASTS Web site is to be redesigned by UNOS to provide the most comprehensive online resources available for transplant surgeons and scientists, UNOS said in a press release.
In addition to providing general news and information about the ASTS, the site will offer a secure, password-protected area where ASTS members can easily access abstracts, newsletters, a job board and research information. The resources are intended to enable members to identify overall best practices, improve patient management, generate statistical analyses that can be used as justification for government agency funded studies and clinical trials, identify risk factors for complications, generate predictive models of outcomes and more.
Registry to collect data on therapy for heart failure
The National Institutes of Health (NIH) has awarded the University of Alabama at Birmingham the contract for the development of an Interagency Registry of Mechanical Support for End-Stage Heart Failure program. The program will establish a data and clinical coordinating center to manage a registry of patients receiving a mechanical circulatory support device to treat heart failure.
As a subcontractor of the University of Alabama, UNOS will collect clinical and laboratory data from 50-70 participating hospitals in the US, on patients receiving mechanical circulatory support devices (MCSDs) as destination therapy for end-stage heart failure. The registry will collect data from approximately 2,000 new patients annually over a period of five years.
Approximately 550,000 people in the US are newly diagnosed annually with heart failure. It is estimated that heart failure is the leading or contributory cause in 300,000 deaths each year. For many of the patients MCSDs would be a viable alternative or adjunctive therapy. By collecting data and reporting on patient characteristics, indications, implantation procedures, and adverse events identified by the interagency registry, the MCSD registry will be able to improve clinical evaluation and patient management and help bring about new advancements in device development, the press release said.
The project is funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, NIH, Department of Health and Human Services, under Contract N01-HV-58198. The total contract, $6,338,903 over five years, will be financed 100% by Federal money. The specific amount of UNOS contract was not defined.
|Printer friendly Cite/link Email Feedback|
|Date:||Jun 30, 2005|
|Previous Article:||Excerpts from AST, ASTS positions on public solicitation of donors.|
|Next Article:||Analyzing BMT patient's oral rinse can predict effectiveness of the transplant, if infection will develop.|